KRAS and neoplasm: HRS-4642 exhibited anti-tumor efficacy in preclinical models as well as a disease control rate (DCR) of 94.4% in a phase I trial enrolling patients with advanced solid tumors harboring KRAS G12D mutations including 10 patients with NSCLC [37].